Anti-Kappa light chain antibody [4G7],Abcam,AB1936

Concentration varies from lot to lot and can be provided on request. This product was changed from ascites to tissue culture supernatant in March 2015. Lot numbers higher than GR145316-1 will be from tissue culture supernatant. Please note that the dilutions may need to be adjusted accordingly.

Host

Mouse

Reactivity

Human

Application

IHC-P

Platform ID

BAB987582728

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-Kappa light chain antibody [4G7]
Cat. No.AB1936
HostMouse
IsotypeIgG2a
ReactivityHuman
ApplicationIHC-P
ClonalityMonoclonal
Clone Number4G7
Concentration2 mg/mL Batch dependent concentration
ImmunogenFull Length Protein corresponding to Human IGKV1D-16. The exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.1% Sodium azide Constituents: PBS
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed : 24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed : 20176268, PubMed : 22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed : 17576170, PubMed : 20176268). See full target information IGKV1D-16

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.